Full-Time

Data Engineer

R&D Data Catalyst Team

Posted on 7/5/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Junior, Mid

Hyderabad, Telangana, India

In Person

Category
Data Analysis
Data Engineering
Data & Analytics
Required Skills
Power BI
SQL
AWS
Databricks
Data Analysis
Requirements
  • Master’s degree and 1 to 3 years of Data Engineering experience OR
  • Bachelor’s degree and 3 to 5 years of Data Engineering experience OR
  • Diploma and 7 to 9 years of Data Engineering experience
  • Minimum of 3 years of hands-on experience with BI solutions (Preferable Power BI or Business Objects) including report development, dashboard creation, and optimization.
  • Minimum of 3 years of hands-on experience building Change-data-capture (CDC) ETL pipelines, data warehouse design and build, and enterprise-level data management.
  • Hands-on experience with Databricks, including data engineering, optimization, and analytics workloads.
  • Deep understanding of Power BI, including model design, DAX, and Power Query.
  • Proven experience designing and implementing data mastering solutions and data governance frameworks.
  • Expertise in cloud platforms (AWS), data lakes, and data warehouses.
  • Strong knowledge of ETL processes, data pipelines, and integration technologies.
  • Good communication and collaboration skills to work with cross-functional teams and senior leadership.
  • Ability to assess business needs and design solutions that align with organizational goals.
  • Exceptional hands-on capabilities with data profiling, data transformation, data mastering
  • Success in mentoring and training team members.
Responsibilities
  • Design and build scalable enterprise analytics solutions using Databricks, Power BI, and other modern data tools.
  • Leverage data virtualization, ETL, and semantic layers to balance need for unification, performance, and data transformation with goal to reduce data proliferation.
  • Break down features into work that aligns with the architectural direction runway.
  • Participate hands-on in pilots and proofs-of-concept for new patterns.
  • Create robust documentation from data analysis and profiling, and proposed designs and data logic.
  • Develop advanced sql queries to profile, and unify data.
  • Develop data processing code in sql, along with semantic views to prepare data for reporting.
  • Develop PowerBI Models and reporting packages.
  • Design robust data models, and processing layers, that support both analytical processing and operational reporting needs.
  • Design and develop solutions based on best practices for data governance, security, and compliance within Databricks and Power BI environments.
  • Ensure the integration of data systems with other enterprise applications, creating seamless data flows across platforms.
  • Develop and maintain Power BI solutions, ensuring data models and reports are optimized for performance and scalability.
  • Collaborate with key customers to define data requirements, functional specifications, and project goals.
  • Continuously evaluate and adopt new technologies and methodologies to enhance the architecture and performance of data solutions.
Desired Qualifications
  • ITIL Foundation or other relevant certifications (preferred)
  • SAFe Agile Practitioner (6.0)
  • Microsoft Certified: Data Analyst Associate (Power BI) or related certification.
  • Databricks Certified Professional or similar certification.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The company's goal is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.